Fig. 1From: Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysisModel structure. All patients start preventive migraine treatment. Patients who at the end of 12 weeks have been classified as responders were assessed in the long term whether they remained on treatment or discontinued. Non-responders went directly to discontinuation status. Mortality was not considered as an individual health state, since this can occur to all patients, whatever their health status may be. Thus, the absorbing state for mortality is negative discontinuationBack to article page